Larimar Therapeutics Inc
$ 3.60
4.65%
11 Jun - close price
- Market Cap 357,357,000 USD
- Current Price $ 3.60
- High / Low $ 3.64 / 3.44
- Stock P/E N/A
- Book Value 1.51
- EPS -2.12
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.57 %
- ROE -1.10 %
- 52 Week High 6.42
- 52 Week Low 2.22
About
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. The company is headquartered in Bala Cynwyd, Pennsylvania.
Analyst Target Price
$15.11
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-19 | 2025-11-05 | 2025-08-14 | 2025-04-30 | 2025-03-24 | 2024-10-30 | 2024-08-07 | 2024-05-09 | 2024-03-14 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -0.31 | -0.73 | -0.61 | -0.41 | -0.46 | -0.45 | -0.24 | -0.34 | -0.27 | -0.3 | -0.21 | -0.19 |
| Estimated EPS | -0.4815 | -0.49 | -0.4128 | -0.4803 | -0.4091 | -0.3194 | -0.37 | -0.31 | -0.23 | -0.25 | -0.22 | -0.19 |
| Surprise | 0.1715 | -0.24 | -0.1972 | 0.0703 | -0.0509 | -0.1306 | 0.13 | -0.03 | -0.04 | -0.05 | 0.01 | 0 |
| Surprise Percentage | 35.6179% | -48.9796% | -47.7713% | 14.6367% | -12.4419% | -40.8892% | 35.1351% | -9.6774% | -17.3913% | -20% | 4.5455% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LRMR
2026-05-29 00:10:31
J.P. Morgan has initiated coverage on Larimar Therapeutics (LRMR.US) with a Buy rating. The financial institution has set a target price of $9 for the company's stock.
2026-05-28 06:40:45
JP Morgan has initiated coverage of Larimar Therapeutics (LRMR) with an "Overweight" rating. This indicates that the firm believes LRMR stock will likely outperform the average return of the stocks that JP Morgan covers over the next 12-18 months.
2026-05-27 13:08:38
80,590,392 shares of Common Stock of Larimar Therapeutics, Inc. (LRMR) are under a lock-up agreement set to expire on May 27, 2026. This lock-up prevents executive officers, directors, and certain security holders from selling or transferring shares for 90 days following February 25, 2026, without the consent of J.P. Morgan Securities LLC and Guggenheim Securities, LLC. This measure is typically put in place to stabilize the stock price after a public offering.
2026-05-27 11:41:08
Certain stock options of Larimar Therapeutics, Inc. are subject to a lock-up agreement that concludes on May 27, 2026. This agreement, spanning 91 days from February 25, 2026, prevents executive officers, directors, and specified security holders from selling or transferring common stock or convertible securities without underwriter consent.
2026-05-27 08:26:00
Certain Restricted Stock Units of Larimar Therapeutics, Inc. are locked up from February 25, 2026, to May 27, 2026. This 91-day lock-up period prevents executive officers, directors, and other security holders from selling or transferring common stock or convertible securities without underwriter consent. The agreement ensures stability following a public offering.
2026-05-27 06:09:58
JPMorgan initiated coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Overweight rating and a $9.00 price target, citing significant upside potential from its current trading price of $3.47. The company's lead asset, nomlabofusp, is a treatment for Friedreich's ataxia, with anticipated topline results and FDA feedback in Q2 2026, and a rolling BLA submission expected in June 2026. Other analysts have also reiterated positive outlooks, with price targets ranging from $12.00 to $26.00, reflecting confidence in the company's regulatory progress and strategic initiatives.
